Arkansas Baptist College president Dr. Leslie McClellon resigns
LITTLE ROCK, Ark. – On Monday evening, Arkansas Baptist College said that president Dr. Leslie McClellon has resigned from her position at the school. McClellon took over as president at the institution on Nov. 1, 2024.
In a release announcing McClellon's resignation, ABC officials also highlighted that the school is facing 'extreme financial challenges,' citing a decline in enrollment.
'We are grateful for Dr. McClellon's efforts,' Board Chairman Bill Walker said in accepting McClellon's resignation. 'However, we must immediately change the trajectory of this historic institution if we are to survive and thrive again. We are currently facing extreme financial challenges. We must recommit this institution to the mission of serving those who would not otherwise be served, or the doors of this college will be forever closed.'
Arkansas Baptist College employees say there's been delays in paychecks, officials say it's being 'addressed'
In the statement, the school said that 'Recent news media coverage regarding financial challenges at ABC are rooted in a decline of enrollment to the lowest the College has seen since 2006,' after some in Dec. 2024 that they and others hadn't been paid since Oct. 31.
ABC officials said the school's board has asked that former ABC employee Dr. George Hertz to serve as interim president.
'The college's previous successes in rebounding from significant fluctuations in enrollment is evidence of the significant demand and critical need for the purpose driven, quality education ABC delivers to the communities it serves,' Hertz said. 'No other institution in America is as committed to its students before, during, and after their time at ABC as our faculty, staff, alumni, and donors. ABC has consistently provided a quality educational program delivered in an environment of understanding and compassion that welcomes and supports our students no matter their circumstances. Once again, l expect ABC to respond appropriately, not only surviving but thriving as we continue to meet the needs of those we serve.'
Arkansas Baptist College honors student who lost life to gun violence
Arkansas Baptist College is a private college that was founded in 1884 as the Minister's Institute and is the only historically black Baptist college west of the Mississippi River.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Australia 'confident' in US nuclear sub deal despite review
Australia said Thursday it is "very confident" in the future of a US agreement to equip its navy with a fleet of nuclear-powered submarines, after the Trump administration put the pact under review. The 2021 AUKUS deal joins Australia, the United Kingdom and the United States in a multi-decade effort to balance China's growing military might. It aims to arm Australia with a fleet of cutting-edge, nuclear-powered submarines from the United States, and cooperate in developing an array of warfare technologies. US President Donald Trump's administration has advised Australia and the United Kingdom that it is reviewing AUKUS, a spokesperson for the Australian Defence Department confirmed Thursday. Defence Minister Richard Marles said he was "very confident" Australia would still get the American submarines. "I think the review that's been announced is not a surprise," he told public broadcaster ABC. "We've been aware of this for some time. We welcome it. It's something which is perfectly natural for an incoming administration to do." Australia plans to acquire at least three Virginia Class submarines from the United States within 15 years, eventually manufacturing its own subs. - 'Time to wake up?' - The US navy has 24 Virginia-class vessels, which can carry cruise missiles, but American shipyards are struggling to meet production targets set at two new boats each year. Critics question why the United States would sell nuclear-powered submarines to Australia without stocking its own military first. Marles said boosting the US production of US Virginia Class submarines was a challenge. "That's why we are working very closely with the United States on seeing that happen. But that is improving," he said. Government forecasts estimate the submarine programme alone could cost Australia up to US$235 billion over the next 30 years, a price tag that has contributed to criticism of the strategy. Australia should conduct its own review of AUKUS, said former conservative prime minister Malcolm Turnbull, noting that Britain and now the United States had each decided to re-examine the pact. "Australia, which has the most at stake, has no review. Our Parliament to date has been the least curious and least informed. Time to wake up?," he posted on X. Former Labor Party prime minister Paul Keating, a vehement critic of AUKUS, said the US review might "save Australia from itself". Australia should carve its own security strategy "rather than being dragged along on the coat tails of a fading Atlantic empire", Keating said. - 'Good deal for the US' - Any US review of AUKUS carries a risk, particularly since it is a Biden-era initiative, said Euan Graham, senior analyst at the Australian Strategic Policy Institute. But it is "fundamentally a good deal for the US", he said, with Australia already investing cash to boost American submarine production as part of the agreement. "I just do not think it is realistic for Australia, this far backed in, to have any prospect of withdrawing itself from AUKUS," Graham told AFP. "I don't think there is a plan B that would meet requirements, and I think it would shred Australia's reputation fundamentally in a way that would not be recoverable." djw/lec/hmn
Miami Herald
5 hours ago
- Miami Herald
Shark Tank's Kevin O'Leary warns Americans on 401(k)s
Most American workers generally understand that Social Security monthly paychecks will one day significantly contribute to their future retirement income. But because those Social Security benefits are not by themselves enough to provide people with the financial resources they need to live on comfortably, most also recognize that 401(k) plans and IRAs (Individual Retirement Accounts) are additional tools necessary for securing their financial future. However, finding the extra money to contribute to these accounts can be a significant challenge. Kevin O'Leary, a prominent entrepreneur and investor widely known for his appearances on ABC's "Shark Tank," shares a method that enables workers to cut expenses and direct more money toward their 401(k) and IRA savings. He also offers a stark financial warning. Don't miss the move: Subscribe to TheStreet's free daily newsletter Participating in an employer-sponsored 401(k) plan is a dependable way to build retirement savings, especially when employers offer matching contributions. With automatic payroll deductions, this method allows employees to invest in their future effortlessly, making it both practical and efficient. Related: Jean Chatzky sends strong message to Americans on Social Security IRAs, on the other hand, provide a wider selection of investment options not typically available through 401(k) plans. However, they require more hands-on management, as individuals must open an account and set up automatic contributions independently. In addition to a major warning, O'Leary offers valuable advice on how individuals can cut costs and increase their retirement contributions, which for many Americans primarily consist of 401(k) plans. Many workers who are committed to contributing as much money as they can toward their 401(k) plans find it difficult to do so because their spending habits leave little left to put away for the future. In fact, O'Leary emphasizes, many people spend more than they make - and are working in large part to finance their debts and pay their bills. "You are in constant fear of losing your job, or of your assets losing their value. You worry that one big, unexpected bill might put you under for good, and then you avoid that thought," described O'Leary in his book, "Cold Hard Truth on Men, Women and Money." "You're avoiding the phone and people to whom you owe money. Maybe you're retreating from friends and family out of fear or shame," O'Leary continued. "You're steeped in magical thinking about money - for example, believing you're one lottery ticket, inheritance, or windfall away from total financial transformation." "You wake up in despair and you go to bed defeated. You don't live within your means because you don't even know what they are." More on retirement: Jean Chatzky shares major statement about Social SecurityDave Ramsey sounds alarm for Americans on retirementScott Galloway warns Americans on 401(k), US economy threat O'Leary explains that people who feel this describes them to any degree should correct it immediately. He offers a first step people can take to get a handle on where they stand financially. Related: Dave Ramsey warns Americans on Social Security In order to increase retirement savings and add a larger percentage of their income to 401(k) plans, people first need to get a good feel for where they are financially. O'Leary suggests simplifying money management down to a single figure - either positive or negative. He encourages individuals to calculate their total earnings over three months, calling this their 90-Day Number. The process starts with identifying income. If pay stubs aren't easily accessible, reviewing bank statements can help track all incoming funds, including salaries, side jobs, and other sources of cash flow. Next, he recommends listing all expenses separately - small purchases such as coffee, clothing, and snacks, as well as major costs such as bills, debt payments, rent, and car loans. The key step is subtracting total expenses from total income. If the result is positive, the individual is in good financial shape and can immediately consider increasing their 401(k) contributions. A negative outcome signals a need for adjustments. The extent of necessary changes depends on how much spending exceeds earnings, requiring smarter budgeting to create space for investments in long-term financial security, O'Leary explains. In the latter instance - after some planning, budgeting and hard work - a person can still reach the point of increasing investments in their 401(k) plans. Related: Dave Ramsey sends major message to Americans on IRAs, Roth IRAs The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
6 hours ago
- Yahoo
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of Directors David Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J. Bachleda, PharmD, MBA as an independent member of the Board of Directors, David Shook, MD as Chief Medical Officer, and Mark Meltz, JD as General Counsel and Corporate Secretary. These appointments, along with the appointment earlier in the year of Jarrad Aguirre, MD, MBA as Senior Vice President, Medical Affairs, further strengthen the Company's clinical and commercial capabilities. 'As Lyell prepares to move forward with two pivotal programs designed to advance LYL314 towards approval for patients with aggressive large B-cell lymphoma, we are delighted to welcome leaders who further strengthen and bring new expertise to our Board of Directors and our Executive Committee,' said Lynn Seely, MD, Lyell's President and Chief Executive Officer. 'Collectively, these new leaders have deep cell therapy expertise and highly relevant experience launching new medicines for patients. We look forward to their contributions as we continue to make progress on achieving our mission of bringing next-generation cell therapies to patients with cancer.' 'The addition of Dr. Bachleda to the Lyell Board provides us with experienced commercial leadership, including in cell therapy, at this critical time as Lyell becomes a late-stage clinical company initiating pivotal clinical trials and anticipating a commercial launch of LYL314,' said Rick Klausner, MD, Chairman of the Lyell Board of Directors. 'I could not be more pleased with the progress the company is making and am confident that our new executive leaders will ensure operational excellence as we focus on rapidly advancing LYL314, our autologous CD19/CD20 CAR T-cell therapy, to patients.' Mark J. Bachleda, PharmD, MBA appointed independent member of the Board of Directors Dr. Bachleda is currently the Chief Executive Officer and a member of the Board of Directors of Eyconis, Inc., a biopharmaceutical company focused on developing therapeutics for eye diseases. He has served in executive leadership roles at Amgen, Juno Therapeutics, and Bristol Myers Squibb (BMS), and, most recently, he was Chief Commercial Officer at Galera Therapeutics. Prior to joining Galera, he served as Vice President & U.S. Business Unit Head of the CAR T-cell therapy franchise at BMS, a role he held previously at Celgene Corporation before its acquisition by BMS. Prior to this, he was Vice President, Sales & Account Management at Juno when it was acquired by Celgene. His experience includes a 15-year career at Amgen in the U.S. and international roles of increasing responsibility up to Country President & General Manager of Amgen Czech Republic. Earlier in his career, he held positions at Pfizer, Inc., and Johnson & Johnson. Dr. Bachleda is a registered pharmacist and received his PharmD degree from the University of Illinois at Chicago. He completed a post-doctoral fellowship in health policy and economics at Thomas Jefferson University and earned MBA degrees from both Columbia University and the University of California, Berkeley. David Shook, MD appointed Chief Medical Officer Dr. Shook is an early pioneer of cell therapy and remains a practicing pediatric oncologist and transplant physician. Prior to Lyell, Dr. Shook was Chief Medical Officer and Head of Research and Development at Nkarta where he was responsible for leading the clinical development of multiple CAR NK cell product candidates for oncology. Prior to joining Nkarta, Dr. Shook held roles as Medical Director, Pediatric Cellular Therapy at AdventHealth and was Fellowship Director and a Faculty Member at St. Jude Children's Research Hospital. While at St. Jude, he conducted multiple first-in-human cell therapy trials, as well as research in the laboratory of Dario Campana, MD, PhD where he co-developed the membrane bound form of interleukin-15. He earned an MD from The Johns Hopkins University School of Medicine and a BS from Purdue University. Mark Meltz, JD appointed General Counsel and Corporate Secretary Mr. Meltz is an accomplished legal and business executive with more than two decades of experience leading and advising life sciences, technology and emerging growth companies. Prior to joining Lyell, Mr. Meltz was Chief Operating Officer and General Counsel of Kinnate Biopharma Inc., a clinical stage precision oncology company, through its sale to XOMA Corporation. Before Kinnate, he was Senior Vice President and General Counsel of Audentes Therapeutics through its sale to Astellas Pharma. Mr. Meltz also was previously Executive Vice President and Chief Business Development and Legal Officer at PaxVax through its sale to Emergent BioSolutions. Earlier in his career, Mr. Meltz was Associate General Counsel at Biogen and Head of Legal for North America at Novartis in its Vaccines & Diagnostics division. Mr. Meltz has supported multiple commercial launches at PaxVax, Biogen and Novartis. He earned a BA with Departmental Honors in Psychology from Yale University and a JD, Magna Cum Laude, from Boston College Law School. Jarrad Aguirre, MD, MBA appointed Senior Vice President, Medical Affairs Dr. Aguirre joined Lyell as Senior Vice President, Medical Affairs in January 2025. Prior to Lyell, Dr. Aguirre was Co-Founder and Chief Executive Officer of Miga Health, a digital health company focused on heart health, through its sale to Bitterroot Bio. Before Miga Health, Dr. Aguirre served in leadership roles at Myovant Sciences, most recently as Head of Corporate Strategy. Dr. Aguirre earned an MD and an MBA from Stanford University, an MPhil in Medical Anthropology from the University of Oxford as a Rhodes Scholar, and a BS in Biology from Yale University. About Lyell Immunopharma, Inc. Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. To learn more, please visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the performance of the Company's additions to its leadership team and Board of Directors, including the anticipated benefits of expanded strength of the Company's clinical and commercial capabilities; the continued clinical progress and anticipated commercial launch of the LYL314 trials; Lyell's anticipated progress, business plans, business strategy and clinical trials; Lyell's advancement of its pipeline, technology platform and research, development and clinical capabilities; the potential clinical benefits and therapeutic potential of Lyell's product candidates; and other statements that are not historical fact. These statements are based on Lyell's current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: the ability to retain the continued service of its key personnel; the complexity of manufacturing cellular therapies, which subjects Lyell to a multitude of manufacturing risks, any of which could substantially increase our costs, delay Lyell's programs or limit supply of Lyell's product candidates; the effects of macroeconomic conditions, including the effects of disruption between the U.S. and its trading partners due to tariffs or other policies, any geopolitical instability and actual or perceived changes in interest rates and economic inflation; Lyell's ability to initiate or progress clinical trials on the anticipated timelines, if at all; Lyell's limited experience as a company in enrolling and conducting clinical trials, and lack of experience in completing clinical trials; the nonclinical profiles of Lyell's product candidates or technology not translating in clinical trials; the potential for results from clinical trials to differ from nonclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with Lyell's product candidates; the significant uncertainty associated with Lyell's product candidates ever receiving any regulatory approvals; Lyell's ability to obtain, maintain or protect intellectual property rights related to its product candidates; implementation of Lyell's strategic plans for its business and product candidates; the sufficiency of Lyell's capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading 'Risk Factors' in Lyell's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on May 13, 2025. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law. Contact: Ellen RoseSenior Vice President, Communications and Investor Relationserose@ in to access your portfolio
